DDInter915 DDInter51
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Alogliptin
Indacaterol {u} (Compound) causes {v} (Side Effect) Diabetes mellitus
Diabetes mellitus {u} (Side Effect) is caused by {v} (Compound) Alogliptin
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Linagliptin
Linagliptin {u} (Compound) resembles {v} (Compound) Alogliptin
Indacaterol {u} (Compound) causes {v} (Side Effect) Diabetes mellitus
Diabetes mellitus {u} (Side Effect) is caused by {v} (Compound) Linagliptin
Linagliptin {u} (Compound) resembles {v} (Compound) Alogliptin
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nelfinavir
Nelfinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Indacaterol {u} (Compound) causes {v} (Side Effect) Diabetes mellitus
Diabetes mellitus {u} (Side Effect) is caused by {v} (Compound) Hydrochlorothiazide
Hydrochlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Indacaterol {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Alogliptin
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is palliated by {v} (Compound) Ephedrine
Ephedrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Indacaterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound)
Indacaterol (Compound) causes Diabetes mellitus (Side Effect) and Diabetes mellitus (Side Effect) is caused by Alogliptin (Compound)
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound) and Linagliptin (Compound) resembles Alogliptin (Compound)
Indacaterol (Compound) causes Diabetes mellitus (Side Effect) and Diabetes mellitus (Side Effect) is caused by Linagliptin (Compound) and Linagliptin (Compound) resembles Alogliptin (Compound)
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nelfinavir (Compound) and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Indacaterol (Compound) causes Diabetes mellitus (Side Effect) and Diabetes mellitus (Side Effect) is caused by Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Indacaterol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Alogliptin
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is palliated by Ephedrine (Compound) and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Indacaterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin